SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2021

Dec. 31, 2020

Accounting Policies [Abstract]

SCHEDULE OF OTHER CURRENT ASSETS

Other current assets consisted of the following as of September 30, 2021 and December 31, 2020:

	September 30, 2021		December 31, 2020
	(unaudited)
Lab supply inventory	$	2,271	$	2,052
Prepaid expenses		734		625
Other		130		45
Total other current assets	$	3,135	$	2,722

Other current assets consisted of the following as of December 31, 2020 and 2019:

	December 31, 2020		December 31, 2019
Lab supply inventory	$	2,052	$	1,825
Prepaid expenses		625		971
Funds in escrow		-		888
Other		45		167
Total other current assets	$	2,722	$	3,851

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
Basic weighted average number of common shares		4,165		4,038		4,119		4,025
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		4,165		4,038		4,119		4,025

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
Options		684		878		684		878
Restricted stock and restricted stock units (RSUs)		366		28		366		28
Warrants		1,405		1,405		1,405		1,405
		2,455		2,311		2,455		2,311

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

	Years Ended December 31,
	2020		2019
Options		849		416
Restricted stock units (RSUs)		238		49
Warrants		1,405		1,420
		2,492		1,885